SLC16A7

Summary

SLC16A7 (solute carrier family 16 member 7, HGNC:10928) is a protein-coding gene on chromosome 12q14.1, encoding Monocarboxylate transporter 2 (O60669). Proton-coupled monocarboxylate symporter.

This gene is a member of the monocarboxylate transporter family. Members in this family transport metabolites, such as lactate, pyruvate, and ketone bodies. The protein encoded by this gene catalyzes the proton-linked transport of monocarboxylates and has the highest affinity for pyruvate. This protein has been reported to be more highly expressed in prostate and colorectal cancer specimens when compared to control specimens. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 9194 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 90 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001270623

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10928
Approved symbol	SLC16A7
Name	solute carrier family 16 member 7
Location	12q14.1
Locus type	gene with protein product
Status	Approved
Aliases	MCT2
Ensembl gene	ENSG00000118596
Ensembl biotype	protein_coding
OMIM	603654
Entrez	9194

Gene structure

Transcript identifiers

Ensembl transcripts: 33 — 24 protein_coding, 6 nonsense_mediated_decay, 3 protein_coding_CDS_not_defined

ENST00000261187, ENST00000546459, ENST00000547379, ENST00000547801, ENST00000548444, ENST00000548610, ENST00000549033, ENST00000549305, ENST00000549465, ENST00000549588, ENST00000549928, ENST00000550062, ENST00000551877, ENST00000552024, ENST00000552405, ENST00000552432, ENST00000858943, ENST00000858944, ENST00000858945, ENST00000858946, ENST00000858947, ENST00000858948, ENST00000858949, ENST00000858950, ENST00000858951, ENST00000858952, ENST00000858953, ENST00000858954, ENST00000858955, ENST00000858956, ENST00000958121, ENST00000958122, ENST00000958123

RefSeq mRNA: 3 — MANE Select: NM_001270623 NM_001270622, NM_001270623, NM_004731

CCDS: CCDS8961

Canonical transcript exons

ENST00000547379 — 6 exons

Exon	Start	End
ENSE00002342427	59779423	59789841
ENSE00002364331	59655152	59655250
ENSE00002409951	59596029	59596236
ENSE00003503119	59774657	59775475
ENSE00003511088	59771219	59771362
ENSE00003664624	59704772	59705018

Expression profiles

Bgee: expression breadth ubiquitous, 286 present calls, max score 98.88.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.9673 / max 454.0499, expressed in 1556 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
126359	8.5989	1472
126360	3.3601	1083
126367	1.2913	68
126358	0.3777	173
126357	0.0986	36
126363	0.0892	23
126365	0.0458	21
126364	0.0357	19
206761	0.0268	20
206762	0.0151	11

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
heart right ventricle	UBERON:0002080	98.88	gold quality
renal medulla	UBERON:0000362	98.36	gold quality
vena cava	UBERON:0004087	97.96	gold quality
pericardium	UBERON:0002407	97.54	gold quality
sperm	CL:0000019	97.16	gold quality
tongue squamous epithelium	UBERON:0006919	96.26	gold quality
cardia of stomach	UBERON:0001162	95.34	gold quality
male germ cell	CL:0000015	94.84	gold quality
left ventricle myocardium	UBERON:0006566	94.72	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	94.25	gold quality
superior surface of tongue	UBERON:0007371	94.24	gold quality
body of tongue	UBERON:0011876	93.92	gold quality
nipple	UBERON:0002030	93.87	gold quality
myocardium	UBERON:0002349	93.57	gold quality
pharyngeal mucosa	UBERON:0000355	93.08	gold quality
biceps brachii	UBERON:0001507	92.97	gold quality
adrenal tissue	UBERON:0018303	92.80	gold quality
oral cavity	UBERON:0000167	92.75	gold quality
tongue	UBERON:0001723	92.74	gold quality
skin of hip	UBERON:0001554	92.39	gold quality
calcaneal tendon	UBERON:0003701	92.29	gold quality
cervix squamous epithelium	UBERON:0006922	92.29	gold quality
esophagus squamous epithelium	UBERON:0006920	92.28	gold quality
squamous epithelium	UBERON:0006914	91.98	gold quality
saphenous vein	UBERON:0007318	91.46	gold quality
superficial temporal artery	UBERON:0001614	91.06	gold quality
endothelial cell	CL:0000115	90.96	gold quality
cauda epididymis	UBERON:0004360	90.94	gold quality
gingiva	UBERON:0001828	90.45	gold quality
Brodmann (1909) area 23	UBERON:0013554	90.12	gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-MTAB-8142	yes	36.32
E-CURD-88	yes	22.57
E-CURD-46	yes	13.29
E-MTAB-6701	yes	11.42
E-GEOD-137537	yes	7.08
E-MTAB-7316	no	859.53
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): PPARA

miRNA regulators (miRDB)

348 targeting SLC16A7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-511-3P	99.99	68.85	1467

Literature-anchored findings (GeneRIF, showing 25)

• MCT2 immunoreactivity was noted in astrocytic cell bodies from week 19 and spread subsequently to the astrocyte end-feet in contact with blood vessels of visual cortex. (PMID:14757520)
• Gamma-hydroxybutyric acid (GHB) is a substrate for both MCT2 and MCT4. (PMID:17502341)
• Colorectal neoplasms showed a loss of expression of MCT2 in plasma membranes. (PMID:18188595)
• These data demonstrate neuronal MCT2 expression in human, but since a portion of it exhibits a distinct synaptic localization, it further supports a putative role for MCT2 in adjustment of energy supply to levels of activity. (PMID:18598673)
• Data suggest that hypoxia increases lactate release from adipocytes and modulates MCT expression in a type-specific manner, with MCT1 and MCT4, but not MCT2 expression, being hypoxia-inducible transcription factor-1 (HIF-1) dependent. (PMID:19876643)
• Ocular absorption of monocarboxylic acid drugs may be enhanced by MCT transporter SLC16A7, and the absorption route provided by this transporter may be utilized to improve the bioavailability of topically applied ophthalmic drugs. (PMID:20035863)
• MCT1, MCT2, and MCT4 protein expression in breast, colon, lung, and ovary neoplasms, as well as CD147 and CD44, were analysed. (PMID:20454640)
• data suggest that extracellular membrane-bound CAIV, but not cytosolic CAII, augments transport activity of MCT2 in a non-catalytic manner, possibly by facilitating a proton pathway other than His-88 (PMID:21680735)
• Data show that a significant increase of MCT2 and MCT4 expression in the cytoplasm of tumour cells and a significant decrease in both MCT1 and CD147 expression in prostate tumour cells was observed when compared to normal tissue. (PMID:21787388)
• Light microscopic immunohistochemistry revealed significantly less perivascular MCT2 immunoreactivity in the hippocampal formation in medial temporal lobe epilepsy than in non-MTLE patients (PMID:22535546)
• The monocarboxylate transporter 2 (MCT2) protein was tumor-selectively expressed in human colorectal malignancies and knockdown of MCT2 induces mitochondrial dysfunction, cell-cycle arrest, and senescence. (PMID:22964484)
• this study provided evidence for the presence of MCT2 in prostate cancer, selectively labeling malignant glands. (PMID:23192371)
• MCT2-3’ UTR SNP (+2626 G > A) had a strong association with oligoasthenoteratozoospermia. (PMID:24799634)
• This study identified that CGPs was found to significantly correlate with the differential expression and methylation of genes encoding solute carrier family 16, member 7. (PMID:25243493)
• SNPs in MCT1 and MCT2 genes may affect clinical outcomes and can be used to predict the response to adjuvant chemotherapy in CRC patients who received surgical treatment. (PMID:25492048)
• Our findings suggest that SNPs in MCT1 and MCT2 genes may affect clinical outcomes and can be used to predict the response to adjuvant chemotherapy in NSCLC patients who received surgical treatment once validated in future study. (PMID:25578492)
• Data suggest that monocarboxylate transporter 2 (MCT2) at peroxisomes is related to an increase in beta-oxidation levels which may be crucial for malignant transformation. (PMID:25639644)
• SLC16A7 (MCT2) epigenetic regulation results in protein over-expression, affecting signalling and cellular phenotypes in prostate cancer (PMID:26035357)
• Adipocytes promote malignant growth of breast tumors with MCT2 expression via beta-hydroxybutyrate. (PMID:28281525)
• MCT2 dictates the mode of action of N-oxalylglycine (NOG) by determining its intracellular concentration (PMID:30297875)
• the present study reports that the combination of tumour stroma percentage and tumour cell expression of cytoplasmic MCT-2 or nuclear LDH-5 is associated with poor prognosis. (PMID:30521130)
• Cooperative transport mechanism of human monocarboxylate transporter 2. (PMID:32415067)
• Identification of the essential extracellular aspartic acids conserved in human monocarboxylate transporters 1, 2, and 4. (PMID:32819565)
• Whole-brain neuronal MCT2 lactate transporter expression links metabolism to human brain structure and function. (PMID:35939682)
• Functional heterogeneity of MCT1 and MCT4 in metabolic reprogramming affects osteosarcoma growth and metastasis. (PMID:36814318)

Cross-species orthologs

17 orthologs

Organism	Symbol	Gene ID
		ENSDARG00000098258
mus_musculus	Slc16a7	ENSMUSG00000020102
rattus_norvegicus	Slc16a7	ENSRNOG00000007839
drosophila_melanogaster	Mct1	FBGN0023549
drosophila_melanogaster	CG14196	FBGN0031002
drosophila_melanogaster	CG8051	FBGN0031012
drosophila_melanogaster	Sln	FBGN0033657
drosophila_melanogaster	CG8468	FBGN0033913
drosophila_melanogaster	Targ	FBGN0033955
drosophila_melanogaster	CG13907	FBGN0035173
drosophila_melanogaster	out	FBGN0259834
caenorhabditis_elegans		WBGENE00003986
caenorhabditis_elegans		WBGENE00010834
caenorhabditis_elegans		WBGENE00015273
caenorhabditis_elegans		WBGENE00015676
caenorhabditis_elegans		WBGENE00020168
caenorhabditis_elegans		WBGENE00021227

Paralogs (13): SLC16A8 (ENSG00000100156), SLC16A6 (ENSG00000108932), SLC16A10 (ENSG00000112394), SLC16A3 (ENSG00000141526), SLC16A2 (ENSG00000147100), SLC16A12 (ENSG00000152779), SLC16A1 (ENSG00000155380), SLC16A14 (ENSG00000163053), SLC16A9 (ENSG00000165449), SLC16A4 (ENSG00000168679), SLC16A5 (ENSG00000170190), SLC16A11 (ENSG00000174326), SLC16A13 (ENSG00000174327)

Protein

Protein identifiers

Monocarboxylate transporter 2 — O60669 (reviewed: O60669)

Alternative names: Solute carrier family 16 member 7

All UniProt accessions (9): O60669, F8VQS4, F8VS95, F8VVU7, F8VXG4, F8VYZ2, F8W0N3, F8W0U4, F8W1M4

UniProt curated annotations — full annotation on UniProt →

Function. Proton-coupled monocarboxylate symporter. Catalyzes the rapid transport across the plasma membrane of monocarboxylates such as L-lactate, pyruvate and ketone bodies, acetoacetate, beta-hydroxybutyrate and acetate. Dimerization is functionally required and both subunits work cooperatively in transporting substrate.

Subunit / interactions. Homodimer. Interacts with GRID2IP. Interacts with EMB; interaction mediates SLC16A7 targeting to the plasma membrane. Interacts with isoform 2 of BSG.

Subcellular location. Cell membrane. Basolateral cell membrane. Cytoplasm.

Tissue specificity. Detected in heart and in blood lymphocytes and monocytes (at protein level). High expression in testis, moderate to low in spleen, heart, kidney, pancreas, skeletal muscle, brain and leukocyte. Restricted expression in normal tissues, but widely expressed in cancer cells.

Activity regulation. Transport activity exhibits steep dependence on substrate concentration. Substrate concentration sensitivity of SLC16A7 arises from the strong inter-subunit cooperativity of the SLC16A7 dimer during transport. Inhibited by AR-C155858.

Similarity. Belongs to the major facilitator superfamily. Monocarboxylate porter (TC 2.A.1.13) family.

RefSeq proteins (3): NP_001257551, NP_001257552, NP_004722 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004743	MCT	Family
IPR011701	MFS	Family
IPR020846	MFS_dom	Domain
IPR036259	MFS_trans_sf	Homologous_superfamily
IPR050327	Proton-linked_MCT	Family

Pfam: PF07690

Catalyzed reactions (Rhea), 7 shown:

• (S)-lactate(in) + H(+)(in) = (S)-lactate(out) + H(+)(out) (RHEA:29415)
• pyruvate(out) + H(+)(out) = pyruvate(in) + H(+)(in) (RHEA:64720)
• acetoacetate(out) + H(+)(out) = acetoacetate(in) + H(+)(in) (RHEA:71775)
• 4-methyl-2-oxopentanoate(out) + H(+)(out) = 4-methyl-2-oxopentanoate(in) + H(+)(in) (RHEA:71779)
• 3-methyl-2-oxobutanoate(out) + H(+)(out) = 3-methyl-2-oxobutanoate(in) + H(+)(in) (RHEA:71783)
• (R)-3-hydroxybutanoate(out) + H(+)(out) = (R)-3-hydroxybutanoate(in) + H(+)(in) (RHEA:71795)
• (S)-3-hydroxybutanoate(out) + H(+)(out) = (S)-3-hydroxybutanoate(in) + H(+)(in) (RHEA:71871)

UniProt features (48 total): mutagenesis site 14, topological domain 13, transmembrane region 12, sequence conflict 3, region of interest 2, chain 1, compositionally biased region 1, site 1, sequence variant 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
9L0C	ELECTRON MICROSCOPY	3.2
9L0B	ELECTRON MICROSCOPY	3.7
7BP3	ELECTRON MICROSCOPY	3.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O60669-F1	84.38	0.70

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 293 (may be protonated during monocarboxylate transport)

Mutagenesis-validated functional residues (14):

Position	Phenotype
18	reduces pyruvate transmembrane transporter activity. no effect on protein abundance. does not affect cell surface locali
20	reduces pyruvate transmembrane transporter activity. no effect on protein abundance. does not affect cell surface locali
34	reduces pyruvate transmembrane transporter activity. no effect on protein abundance. does not affect cell surface locali
38	reduces pyruvate transmembrane transporter activity. no effect on protein abundance. does not affect cell surface locali
70	no effect on protein abundance. does not affect cell surface localization.
143	reduces pyruvate transmembrane transporter activity. reduces pyruvate transmembrane transporter activity. no effect on p
147	reduces pyruvate transmembrane transporter activity. reduces pyruvate transmembrane transporter activity. no effect on p
262	no effect on protein abundance. does not affect cell surface localization.
293	reduced proton-dependent active symport, but not pyruvate transport.
297	reduces pyruvate transmembrane transporter activity. no effect on protein abundance. does not affect cell surface locali
305	reduces pyruvate transmembrane transporter activity. no effect on protein abundance. does not affect cell surface locali
351	reduces pyruvate transmembrane transporter activity. no effect on protein abundance. does not affect cell surface locali
355	reduces pyruvate transmembrane transporter activity. no effect on protein abundance. does not affect cell surface locali
360	reduces pyruvate transmembrane transporter activity. no effect on protein abundance. does not affect cell surface locali

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-433692	Proton-coupled monocarboxylate transport
R-HSA-382551	Transport of small molecules
R-HSA-425366
R-HSA-425407	SLC-mediated transmembrane transport

MSigDB gene sets: 276 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_DN, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOBP_CIRCULATORY_SYSTEM_PROCESS, MODULE_162, GOZGIT_ESR1_TARGETS_DN, HALMOS_CEBPA_TARGETS_UP, RODWELL_AGING_KIDNEY_NO_BLOOD_DN, GOBP_ORGANIC_ACID_TRANSPORT, GOBP_ORGANIC_HYDROXY_COMPOUND_TRANSPORT, BROWNE_HCMV_INFECTION_48HR_DN, SASAI_RESISTANCE_TO_NEOPLASTIC_TRANSFROMATION, DACOSTA_UV_RESPONSE_VIA_ERCC3_TTD_DN, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, GOBP_ORGANIC_ANION_TRANSPORT

GO Biological Process (6): lactate transmembrane transport (GO:0035873), plasma membrane lactate transport (GO:0035879), transport across blood-brain barrier (GO:0150104), pyruvate transmembrane transport (GO:1901475), monocarboxylic acid transport (GO:0015718), transmembrane transport (GO:0055085)

GO Molecular Function (9): pyruvate secondary active transmembrane transporter activity (GO:0005477), lactate transmembrane transporter activity (GO:0015129), symporter activity (GO:0015293), identical protein binding (GO:0042802), pyruvate transmembrane transporter activity (GO:0050833), protein binding (GO:0005515), monocarboxylic acid transmembrane transporter activity (GO:0008028), secondary active monocarboxylate transmembrane transporter activity (GO:0015355), transmembrane transporter activity (GO:0022857)

GO Cellular Component (11): nucleoplasm (GO:0005654), cytosol (GO:0005829), plasma membrane (GO:0005886), basolateral plasma membrane (GO:0016323), Schaffer collateral - CA1 synapse (GO:0098685), hippocampal mossy fiber to CA3 synapse (GO:0098686), parallel fiber to Purkinje cell synapse (GO:0098688), postsynaptic density membrane (GO:0098839), glutamatergic synapse (GO:0098978), cytoplasm (GO:0005737), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
SLC-mediated transport of organic anions	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
carboxylic acid transmembrane transport	2
lactate transmembrane transport	2
monocarboxylic acid transmembrane transporter activity	2
secondary active transmembrane transporter activity	2
carboxylic acid transmembrane transporter activity	2
synapse	2
lactate transport	1
vascular transport	1
pyruvate transport	1
carboxylic acid transport	1
transport	1
cellular process	1
secondary active monocarboxylate transmembrane transporter activity	1
pyruvate transmembrane transporter activity	1
protein binding	1
pyruvate transmembrane transport	1
binding	1
monocarboxylic acid transport	1
transporter activity	1
transmembrane transport	1
nuclear lumen	1
cytoplasm	1
membrane	1
cell periphery	1
basal plasma membrane	1
plasma membrane region	1
thorny excrescence	1
neuron to neuron synapse	1
hippocampal mossy fiber expansion	1
excitatory synapse	1
postsynaptic density	1
postsynaptic membrane	1
postsynaptic specialization membrane	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

936 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC16A7	EMB	Q6PCB8	883
SLC16A7	BSG	P35613	799
SLC16A7	SLC17A5	Q9NRA2	772
SLC16A7	SLC2A3	P11169	606
SLC16A7	SLC16A3	O15427	604
SLC16A7	MCTS1	Q9ULC4	597
SLC16A7	SLC2A1	P11166	588
SLC16A7	SLC5A8	Q8N695	581
SLC16A7	SLC5A12	Q1EHB4	580
SLC16A7	SLC16A4	O15374	579
SLC16A7	HCAR1	Q9BXC0	569
SLC16A7	LDHA	P00338	507
SLC16A7	PEX19	P40855	486
SLC16A7	OXCT1	P55809	444
SLC16A7	SLC16A8	O95907	435

IntAct

175 interactions, top by confidence:

A	B	Type	Score
SCRIB	SLC16A7	psi-mi:“MI:0407”(direct interaction)	0.620
SNTB1	SLC16A7	psi-mi:“MI:0407”(direct interaction)	0.620
SNTA1	SLC16A7	psi-mi:“MI:0407”(direct interaction)	0.620
SLC16A7	SNTA1	psi-mi:“MI:0407”(direct interaction)	0.620
SLC16A7	SCRIB	psi-mi:“MI:0407”(direct interaction)	0.620
IFITM3	SLC16A7	psi-mi:“MI:0915”(physical association)	0.560
VAPA	SLC16A7	psi-mi:“MI:0915”(physical association)	0.560
SFXN1	SLC16A7	psi-mi:“MI:0915”(physical association)	0.560
LEMD1	SLC16A7	psi-mi:“MI:0915”(physical association)	0.560
CDIPT	SLC16A7	psi-mi:“MI:0915”(physical association)	0.560
TIMM23	SLC16A7	psi-mi:“MI:0915”(physical association)	0.560
SLC16A7	VTI1B	psi-mi:“MI:0915”(physical association)	0.560
SLC16A7	IFITM3	psi-mi:“MI:0915”(physical association)	0.560
SLC16A7	COMT	psi-mi:“MI:0915”(physical association)	0.560
SLC16A7	VAPA	psi-mi:“MI:0915”(physical association)	0.560
GPR25	SLC16A7	psi-mi:“MI:0915”(physical association)	0.560
SLC16A7	FXYD6	psi-mi:“MI:0915”(physical association)	0.560
SLC16A7	SFXN1	psi-mi:“MI:0915”(physical association)	0.560
SLC16A7	SMAGP	psi-mi:“MI:0915”(physical association)	0.560
SLC16A7	ACSL5	psi-mi:“MI:0915”(physical association)	0.560
SLC16A7	HMOX1	psi-mi:“MI:0915”(physical association)	0.560
SLC16A7	LEMD1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (44): SLC16A7 (Two-hybrid), SLC16A7 (Two-hybrid), SLC16A7 (Two-hybrid), SLC16A7 (Two-hybrid), SLC16A7 (Two-hybrid), FXYD6 (Two-hybrid), IFITM3 (Two-hybrid), SFXN1 (Two-hybrid), GPR25 (Two-hybrid), SMAGP (Two-hybrid), LEMD1 (Two-hybrid), ACSL5 (Two-hybrid), TIMM23 (Two-hybrid), KTN1 (Proximity Label-MS), SLC16A7 (Affinity Capture-MS)

ESM2 similar proteins: A1L1W9, B0JZE1, D3Z5L6, D4A9K4, F1NJ67, G5E8K6, G8XYX6, O08966, O15375, O35308, O35440, O60669, O70324, O70451, O70461, O94956, P36021, P53985, P53986, P53987, P53988, Q03064, Q05B81, Q0IHM1, Q3MHW6, Q3U9N9, Q5EBA8, Q5TF39, Q63089, Q63344, Q68F72, Q6DCX5, Q6DEJ6, Q6NT16, Q6PDF3, Q6PEM8, Q7ZWG6, Q80T22, Q8BH31, Q8CE47

Diamond homologs: A0LNN5, B1AT66, I1RV24, O15375, O15403, O15427, O35440, O35910, O60669, O70451, O95907, P53985, P53986, P53987, P53988, P57787, P57788, Q03064, Q17QR6, Q3MHW6, Q63344, Q66HE2, Q7RTY0, Q7TMR7, Q8CE94, Q90632, D4A734, G5E8K6, O15374, O35308, O70461, Q503M4, Q5NC32, Q6GM59, Q6P2X9, Q6ZSM3, Q8BGC3, Q8NCK7, Q8R0M8, M0RCI4

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 103 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Ras activation upon Ca2+ influx through NMDA receptor	5	40.8×	8e-06
Unblocking of NMDA receptors, glutamate binding and activation	5	38.8×	8e-06
Negative regulation of NMDA receptor-mediated neuronal transmission	5	38.8×	8e-06
Long-term potentiation	5	34.0×	1e-05
Assembly and cell surface presentation of NMDA receptors	9	32.6×	7e-10
Neurexins and neuroligins	10	28.1×	4e-10
Protein-protein interactions at synapses	6	22.8×	1e-05
RND3 GTPase cycle	5	18.5×	2e-04

GO biological processes:

GO term	Partners	Fold	FDR
establishment or maintenance of epithelial cell apical/basal polarity	11	65.9×	3e-15
protein localization to synapse	6	47.4×	4e-07
receptor clustering	7	45.0×	5e-08
regulation of postsynaptic membrane neurotransmitter receptor levels	7	35.8×	2e-07
cell-cell adhesion	10	10.5×	6e-06
protein-containing complex assembly	8	9.4×	2e-04
protein localization to plasma membrane	6	6.7×	9e-03
chemical synaptic transmission	7	5.6×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

90 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	72
Likely benign	5
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

2579 predictions. Top by Δscore:

Variant	Effect	Δscore
12:59596232:ATAAA:A	donor_gain	1.0000
12:59596233:TAAA:T	donor_gain	1.0000
12:59596234:AAA:A	donor_gain	1.0000
12:59596235:AA:A	donor_gain	1.0000
12:59596236:AG:A	donor_loss	1.0000
12:59596237:G:GG	donor_gain	1.0000
12:59596237:GTAA:G	donor_loss	1.0000
12:59655248:TCT:T	donor_gain	1.0000
12:59655251:G:GG	donor_gain	1.0000
12:59705015:GGAG:G	donor_gain	1.0000
12:59705016:GAGG:G	donor_gain	1.0000
12:59711048:G:GT	donor_gain	1.0000
12:59711066:C:CG	donor_gain	1.0000
12:59771211:T:A	acceptor_gain	1.0000
12:59771214:T:A	acceptor_gain	1.0000
12:59771215:GTA:G	acceptor_loss	1.0000
12:59771216:TA:T	acceptor_loss	1.0000
12:59771217:A:AG	acceptor_gain	1.0000
12:59771218:G:GG	acceptor_gain	1.0000
12:59771218:GGT:G	acceptor_gain	1.0000
12:59771218:GGTC:G	acceptor_gain	1.0000
12:59771359:ACAGG:A	donor_loss	1.0000
12:59771363:G:C	donor_loss	1.0000
12:59771364:T:G	donor_loss	1.0000
12:59596232:A:G	donor_gain	0.9900
12:59655150:A:AG	acceptor_gain	0.9900
12:59655151:G:GG	acceptor_gain	0.9900
12:59655151:GGA:G	acceptor_gain	0.9900
12:59655247:CTCT:C	donor_gain	0.9900
12:59655249:CT:C	donor_gain	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000004014 (12:59774447 A>G,T), RS1000047756 (12:59739178 A>T), RS1000048362 (12:59697774 T>C), RS1000053169 (12:59767116 C>T), RS1000062088 (12:59752932 G>T), RS1000071756 (12:59596130 T>C), RS1000093985 (12:59651073 A>G), RS1000156159 (12:59722283 C>T), RS1000169446 (12:59663600 A>G), RS1000177268 (12:59703542 T>C), RS1000206515 (12:59612609 A>G), RS1000237616 (12:59612362 A>G), RS1000241573 (12:59759030 G>A), RS1000245426 (12:59676122 T>A,C), RS1000257494 (12:59754412 T>C)

Disease associations

OMIM: gene MIM:603654 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST002911_5	Calcium levels	3.000000e-06
GCST002951_16	Response to zileuton treatment in asthma (FEV1 change interaction)	4.000000e-07
GCST005994_13	Hematocrit	4.000000e-08
GCST006575_49	Takayasu arteritis	4.000000e-06
GCST006575_56	Takayasu arteritis	6.000000e-06
GCST007005_6	Logical memory (immediate recall) in normal cognition	3.000000e-06
GCST007006_10	Logical memory (delayed recall) in normal cognition	2.000000e-07
GCST007324_166	Adventurousness	3.000000e-11
GCST007324_89	Adventurousness	5.000000e-09
GCST007325_287	General risk tolerance (MTAG)	1.000000e-12
GCST90014243_16	Kawasaki disease	2.000000e-06

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004838	calcium measurement
EFO:0005921	FEV change measurement
EFO:0004348	hematocrit
EFO:0004874	memory performance
EFO:0008579	risk-taking behaviour

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2073704 (SINGLE PROTEIN), CHEMBL4802068 (SELECTIVITY GROUP)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 159 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL3335793	AZD3965	1	159

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs3763980	Efficacy	3	methotrexate	Juvenile Rheumatoid Arthritis

PharmGKB variants

2 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs3763980	SLC16A7	3	1.50	1	methotrexate
rs12231740	SLC16A7		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC16 family of monocarboxylate transporters

Most potent curated ligand interactions (3 total), top 3:

Ligand	Action	Affinity	Parameter
BAY-8002	Inhibitor	8.3	pIC50
7ACC2	Inhibition	7.96	pIC50
AZD3965	Inhibition	7.7	pKi

ChEMBL bioactivities

3 potent at pChembl≥5 of 3 total, top 3 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.70	Ki	20	nM	AZD3965
6.60	Ki	251	nM	CHEMBL5723356
6.20	IC50	638	nM	MSC-4381

PubChem BioAssay actives

1 with measured affinity, of 11 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
5-[(4S)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methyl-6-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-1-propan-2-ylthieno[2,3-d]pyrimidine-2,4-dione	1931149: Binding affinity to MCT2 (unknown origin) assessed as inhibition constant	ki	0.0200	uM

CTD chemical–gene interactions

52 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases methylation	8
trichostatin A	increases expression, affects cotreatment	4
Air Pollutants	increases abundance, decreases expression, affects cotreatment	4
Tetrachlorodibenzodioxin	affects expression, affects cotreatment, increases expression	4
sodium arsenite	decreases expression, increases abundance	3
Acetaminophen	decreases expression, increases expression	3
Estradiol	affects cotreatment, decreases expression, increases expression	3
Silicon Dioxide	decreases expression	3
Smoke	decreases expression, increases abundance	3
Tretinoin	decreases expression, increases expression, affects expression	3
bisphenol A	increases expression, increases methylation	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
p-Chloromercuribenzoic Acid	decreases expression, affects cotreatment	2
aristolochic acid I	decreases expression	1
bisphenol F	increases expression	1
geldanamycin	increases expression	1
testosterone enanthate	affects expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
methylselenic acid	increases expression	1
coumarin	increases phosphorylation	1
methacrylaldehyde	decreases expression, increases abundance, affects cotreatment	1
gallium arsenide	decreases expression	1
tamibarotene	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	1
2,2’,4,4’,5-brominated diphenyl ether	increases expression	1
3-iodothyronamine	affects uptake	1
bisphenol B	increases expression	1
abrine	decreases expression	1

ChEMBL screening assays

5 unique, capped per target: 3 binding, 2 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2075342	Functional	TP_TRANSPORTER: uptake in Xenopus laevis oocytes	Human monocarboxylate transporter 2 (MCT2) is a high affinity pyruvate transporter. — J Biol Chem
CHEMBL5234425	Binding	Binding affinity to MCT2 (unknown origin) assessed as inhibition constant	Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: A review with structure-activity relationship insights. — Eur J Med Chem

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4I9	HCT116-SLC16A7-KO-c3	Cancer cell line	Male
CVCL_D4IA	HCT116-SLC16A7-KO-c7	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.